Find an Neurological Study in your area

To find out more about current neurological studies you can view a list of studies on the NIHR Clinical Research Network Portfolio Database

Working with the Life Sciences Industry

The NIHR Clinical Research Network has been enormously successful in integrating clinical research into NHS clinical service provision, and both developing and delivering a large practice changing portfolio of clinical trials.

View the neurological disorder specialty profile

Our Studies

neurological disorders homepage

As the most integrated clinical research system in the world, the NIHR supports research studies through our funding programmes, training and supporting health researchers, and providing world-class research facilities. We also support dialogue between the life sciences industry and charities to benefit all, and facilitate the involvement of patients and the public to make research more effective.

Last year (2016/2017) the NIHR supported 241 studies on Neurological disorders. The NIHR supported these studies through our funding programmes and our research schools and units. We also support Neurological disorders research through our research infrastructure and our training and career development awards for researchers.

Impact case study: MS-STAT

This case study looks at the impact that the MS-STAT phase 2 trial has had on advancing the development of a possible treatment for secondary progressive multiple sclerosis (SPMS). The trial took place between 2008-11 and was led by chief investigator Dr Jeremy Chataway, FRCP Consultant Neurologist,  University College London (UCL) Institute of Neurology. As a result of the MS-STAT study, a much larger phase 3 trial (MS-STAT2) has now begun.

Immune system malfunction after brain trauma

The ‘Golden Hour’ study, supported by the NIHR Surgical Reconstruction and Microbiology Research Centre (SRMRC), is assessing what happens to the immune system within the first 60 minutes from the moment of traumatic injury.

The study found that traumatic injury resulted in immediate immune dysfunction, with both immune activation and suppression detected within minutes across many immune cells and molecules. Some of the immune changes recorded immediately after trauma were no longer present several hours later.

Role of ‘daydreaming’ brain network

A team supported by the NIHR Cambridge Biomedical Research Centre have carried out a study using MRI to measure changes in brain oxygen levels in participants carrying out a card matching task.

The researchers found that the ‘default mode network’ (DMN) in the brain, previously associated with daydreaming, plays an important role in allowing us to perform tasks on autopilot.

The most interesting difference in brain activity was found when comparing the stage at which participants were learning the rules of the task and the stage at which participants applied these rules - the latter was when DMN was more active. They found that in those with a stronger relationship between activity in the DMN and regions of the brain associated with memory during the stage of applying task rules, the more accurately they performed the task.

Statins for multiple sclerosis

A phase 3 trial funded by the NIHR Health Technology Assessment (HTA) Programme is investigating whether statins could become a treatment for people with multiple sclerosis (MS).

The trial is testing simvastatin, a cheap cholesterol lowering drug, in people with the secondary progressive form of MS. There are currently no licensed treatments that can slow or stop disability progression in people with this type of MS.

Melatonin for children with neurodevelopmental disorders and impaired sleep

The NIHR NIHR Clinical Research Network (CRN) Neurological Disorders Specialty is supporting the MElatonin in children with Neurodevelopmental Disorders and impaired Sleep: a randomised, double blind, placebo-controlled, parallel study (MENDS).

A great example of our commitment to widen access to patients is the MENDS study

Community paediatricians identified children in care or being looked after by their extended family.  This required working with local authorities, social services and the children’s families to gain consent but it was a valuable approach to widening access to a very difficult to reach patient population.

You can find out more about Neurological Disorders studies in your area through the UK Clinical Trials Gateway.